Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - A benzodiazepine derivative used mainly as a hypnotic. [PubChem] (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # "Link":http://www.inchem.org/documents/pims/pharm/pim640.htm # Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2883820 # Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15089115 # Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2570451 # Rooke KC: The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice. J Int Med Res. 1976;4(5):355-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18375 # Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine] Arch Fr Pediatr. 1977 Jan;34(1):74-89. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/851373 (en)
|
http://linked.open...gy/drugbank/group
| - approved (en)
- illicit (en)
|
http://linked.open...drugbank/halfLife
| - The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours (en)
|
http://linked.open...ugbank/indication
| - For short-term and intermittent use in patients with recurring insomnia and poor sleeping habits (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Flurazepam binds to an allosteric site on GABA-A receptors. Binding potentiates the action of GABA on GABA-A receptors by opening the chloride channel within the receptor, causing chloride influx and hyperpolarization. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...outeOfElimination
| - Flurazepam is rapidly metabolized and is excreted primarily in the urine. Less than 1% of the dose is excreted in the urine as N1-desalkyl-flurazepam. (en)
|
http://linked.open.../drugbank/synonym
| - Flurazepam (en)
- Insumin (en)
- Flurazepamum (en)
- Flurazépam (en)
|
http://linked.open...drugbank/toxicity
| - Coma, confusion, low blood pressure, sleepiness (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...k/foodInteraction
| - Avoid alcohol. (en)
- Take without regard to meals. (en)
|
http://linked.open...nk/proteinBinding
| |
http://linked.open...ogy/drugbank/salt
| |
http://linked.open...ynthesisReference
| - Fryer, R. and Sternbach, L.H.; U.S. Patent 3,567,710; March 2, 1971; assigned to Hoffman-La Roche, Inc. (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Flurazepam hydrochloride is rapidly (30 minutes) absorbed from the gastrointestinal tract (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...gbank/containedIn
| |